TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7405249

Group type: EXPERIMENTAL
Intervention: Dimeditiapramine (1 mg/kg body weight, single intravenous dose)
Number of subjects: 10
Study: 30296475

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (Tissucol Duo) applied to one hemipelvis
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (hemipelvis not treated with fibrin sealant)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Overall incidence of lymphocele
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Mean initial LC maximum diameter
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Mean LC maximum diameter after one year
Number of subjects: 74
Study: 28958851

Group type: EXPERIMENTAL
Intervention: Liraglutide (3.0 mg, subcutaneous, escalated by 0.6 mg/day for 5 weeks, continued until week 16)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Liraglutide (3.0 mg, subcutaneous)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 26264043

Group type: EXPERIMENTAL
Intervention: PC-PART Self Care scale
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: PC-PART Domestic Life scale
Number of subjects: 996

Group type: COMPARATOR
Intervention: FIM
Number of subjects: 996
Study: 23785020

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (1st week 0.01 mg/day/kg, 2nd week 0.02 mg/day/kg, 3rd week 0.03 mg/day/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GH receptor antagonist (Pegvisomant) treatment (1st week 10 mg/day, last 2 weeks 15 mg/day)
Number of subjects: 8
Study: 20495818

Group type: EXPERIMENTAL
Intervention: Diaton tonometer
Number of subjects: 129

Group type: COMPARATOR
Intervention: Corrected Goldmann applanation tonometry (c-GAT)
Number of subjects: 129
Study: 18230945

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR) training for 25 min/week during weeks 2-8
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard care (control group) including 2 days/week of exercise, education, and psychosocial support
Number of subjects: 83
Study: 16698136

Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) tube feeding with low residual (Osmolite‐HN)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) tube feeding with high-fat (Pulmocare)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) tube feeding with glutamine-containing (AlitraQ)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Nasojejunal (NJ) tube feeding with low residual (Osmolite‐HN)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Nasojejunal (NJ) tube feeding with high-fat (Pulmocare)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Nasojejunal (NJ) tube feeding with glutamine-containing (AlitraQ)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) feeding
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Nasojejunal (NJ) feeding
Number of subjects: 140
Study: 14666956

Group type: EXPERIMENTAL
Intervention: Structured care with atorvastatin (10-80 mg/day, mean 23.7 mg/day)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Usual care (physician's standard of care)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Structured care with atorvastatin
Number of subjects: 313
Study: 10960166

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion tests
Number of subjects: 24
Study: 8838966

Group type: EXPERIMENTAL
Intervention: Oral ampicillin 1 g every 8 hours for 7 days
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 1283893

Group type: EXPERIMENTAL
Intervention: Finasteride therapy for one week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical castration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biologically active DHT equivalent following finasteride
Number of subjects: 0
Study: 3966370

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) alone
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) combined with hydralazine, prazosin, oxprenolol, and propranolol
Number of subjects: 320
Study: 31138273

Group type: EXPERIMENTAL
Intervention: Implementation project 'Don't forget the mouth!'
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group receiving oral health care as usual
Number of subjects: 14
Study: 29985459

Group type: EXPERIMENTAL
Intervention: Nurse-led repeated prescription (NRP)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 393
Study: 27061876

Group type: EXPERIMENTAL
Intervention: High levels of habitual physical activity
Number of subjects: 629
Study: 25281504

Group type: EXPERIMENTAL
Intervention: High-speed circuit (HSC) training
Number of subjects: 21

Group type: COMPARATOR
Intervention: Strength/hypertrophy (SH) training
Number of subjects: 21
Study: 22889759

Group type: EXPERIMENTAL
Intervention: Bortezomib plus thalidomide (VT)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Bortezomib plus prednisone (VP)
Number of subjects: 178
Study: 19680697

Group type: EXPERIMENTAL
Intervention: Nano‐HA paste with papilla preservation flaps
Number of subjects: 14

Group type: COMPARATOR
Intervention: Papilla preservation flaps alone
Number of subjects: 14
Study: 17654295

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study: 17472838

Group type: EXPERIMENTAL
Intervention: supplemented very-low-protein diet (sVLPD)
Number of subjects: 112

Group type: COMPARATOR
Intervention: dialysis
Number of subjects: 112
Study: 15349539

Group type: EXPERIMENTAL
Intervention: Kock pouch
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Kock neobladder
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Mainz‐II pouch
Number of subjects: 58
Study: 10786742

Group type: EXPERIMENTAL
Intervention: i.v. tenoxicam 20 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no tenoxicam)
Number of subjects: 50
Study: 9113635

Group type: EXPERIMENTAL
Intervention: High-AA diet (1.5 g/d)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-AA diet (basal diet)
Number of subjects: 10
Study: 8368552

Group type: EXPERIMENTAL
Intervention: Dezocine (5 mg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Morphine (5 mg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Nalbuphine (5 mg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 84
Study: 3752420

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy with birch pollen extract (20 X 10(6) BU monthly, daily for seven consecutive days every month or once weekly)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy with birch pollen extract (more than 2 X 10(5) BU monthly)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy with birch pollen extract
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31394910

Group type: EXPERIMENTAL
Intervention: Yoga (twice a week for 8 weeks)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 67
Study: 29541538

Group type: EXPERIMENTAL
Intervention: Real tDCS (2 mA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 15
Study: 27017151

Group type: EXPERIMENTAL
Intervention: Treated patients
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Untreated patients
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Stratified by LDLR functionality
Number of subjects: 167
Study: 24718821

Group type: COMPARATOR
Intervention: Best Supportive Care (BSC)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Radiotherapy (<60 gy)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Higher doses of radiotherapy (>30 gy to <60 gy)
Number of subjects: 421
Study: 23122434

Group type: EXPERIMENTAL
Intervention: High-density foam wedge used on school chairs
Number of subjects: 185

Group type: COMPARATOR
Intervention: Normal school seating (Control)
Number of subjects: 185
Study: 19786525

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) intervention
Number of subjects: 84

Group type: COMPARATOR
Intervention: Previous study using the same process measure (AIS) for smoking cessation
Number of subjects: 84
Study: 17145164

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRE)
Number of subjects: 0
Study: 14981214

Group type: EXPERIMENTAL
Intervention: Moderate dose of methylphenidate (0.5 mg/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low dose of methylphenidate (0.5 mg/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High dose of methylphenidate (1.0 mg/kg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 11182173

Group type: EXPERIMENTAL
Intervention: Captopril plus 25 mg i.v. of canreonate (1 mg/h for the 1st 72 h and then orally 25 mg/day)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Captopril and placebo
Number of subjects: 55
Study: 9638313

Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate (GS) at a daily dose of 1,500 mg for 4 weeks
Number of subjects: 178

Group type: COMPARATOR
Intervention: Ibuprofen (IBU) at a daily dose of 1,200 mg for 4 weeks
Number of subjects: 178
Study: 8304303

Group type: EXPERIMENTAL
Intervention: Triple therapy for 1 wk plus omeprazole for 4 wk (Triple+OMP)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Omeprazole alone for 4 wk (OMP)
Number of subjects: 155
Study: 3054251

Group type: EXPERIMENTAL
Intervention: Hydroxypropylmethylcellulose (HPMC) 2% solution
Number of subjects: 65

Group type: COMPARATOR
Intervention: Balanced salt solution (control)
Number of subjects: 65
Study: 31058716

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg daily)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Granisetron (2 mg daily)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 28842402

Group type: EXPERIMENTAL
Intervention: Family-based behavioral treatment (FBT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Attention-controlled information control (IC)
Number of subjects: 96
Study: 26555348

Group type: EXPERIMENTAL
Intervention: IIV3-HD
Number of subjects: 300
Study: 23390069

Group type: EXPERIMENTAL
Intervention: Intralesional antimony (IL Sb) 650 µg/mm² on days 1, 3, and 5
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cryotherapy on days 1 and 14
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo cream daily for 20 days
Number of subjects: 80
Study: 20920142

Group type: EXPERIMENTAL
Intervention: SFC plus Tio (50/250 µg twice daily plus 18 µg once daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tio alone (18 µg once daily)
Number of subjects: 30
Study: 19686407

Group type: EXPERIMENTAL
Intervention: pantoprazole 40 mg, 4 mg/h infusion
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: pantoprazole 80 mg bolus followed by 8 mg/h
Number of subjects: 61

Group type: COMPARATOR
Intervention: pantoprazole 40 mg bolus injection every 24 h
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: H. pylori (−) group with continuous infusion
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: H. pylori (+) group with continuous infusion
Number of subjects: 61
Study: 17908973

Group type: EXPERIMENTAL
Intervention: Caspase-3 activity lower than the median in tumor tissue
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Caspase-3 activity in preoperative biopsies
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Caspase-3 activity lower than the median in tumor tissue (adjusted)
Number of subjects: 117
Study: 14718459

Group type: EXPERIMENTAL
Intervention: Premixed 50% nitrous oxide and oxygen
Number of subjects: 105

Group type: COMPARATOR
Intervention: Premixed 50% nitrogen and oxygen (control group)
Number of subjects: 105
Study: 15197055

Group type: EXPERIMENTAL
Intervention: Topical ocular hypotensive medication
Number of subjects: 408
Study: 11106123

Group type: EXPERIMENTAL
Intervention: CPT-11 + LFA-5-FU (arm A)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: TOM + LFA-5-FU (arm B)
Number of subjects: 159

Group type: COMPARATOR
Intervention: MTX + LFA-5-FU (arm C)
Number of subjects: 159
Study: 9083713

Group type: EXPERIMENTAL
Intervention: Patient-focused pharmacist intervention in community pharmacies; includes targeted patient education, systematic patient monitoring, feedback and behavior modification, and communication with physicians.
Number of subjects: 589

Group type: COMPARATOR
Intervention: Control group (nonparticipating pharmacies); no specific intervention reported.
Number of subjects: 589
Study: 8246275

Group type: EXPERIMENTAL
Intervention: Clomipramine 25 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clomipramine 50 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3532752

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrendipine + Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study: 30411132

Group type: EXPERIMENTAL
Intervention: Sonicare for kids (SFK)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Manual toothbrush (MTB)
Number of subjects: 180
Study: 27084959

Group type: EXPERIMENTAL
Intervention: VX-509 100 mg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: VX-509 200 mg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: VX-509 300 mg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: VX-509 (all doses)
Number of subjects: 43
Study: 24952856

Group type: EXPERIMENTAL
Intervention: Acarbose, an α‐glucosidase inhibitor that lowers postprandial blood glucose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lifestyle modification or pharmacological intervention
Number of subjects: 0
Study: 23167223

Group type: EXPERIMENTAL
Intervention: Medtronic Mosaic Ultra valve
Number of subjects: 141

Group type: COMPARATOR
Intervention: Carpentier‐Edwards PERIMOUNT Magna valve
Number of subjects: 141
Study: 20378636

Group type: EXPERIMENTAL
Intervention: Immediate testing and treatment for chlamydial infection
Number of subjects: 2529

Group type: COMPARATOR
Intervention: Deferred screening controls
Number of subjects: 2529

Group type: COMPARATOR
Intervention: Control women who tested positive for chlamydial infection at baseline
Number of subjects: 2529

Group type: EXPERIMENTAL
Intervention: Screened women who tested positive for chlamydial infection at baseline
Number of subjects: 2529

Group type: EXPERIMENTAL
Intervention: Women who tested negative for chlamydia at baseline
Number of subjects: 2529

Group type: EXPERIMENTAL
Intervention: Overall testing during the trial
Number of subjects: 2529
Study: 18552239

Group type: EXPERIMENTAL
Intervention: Lactate-buffered fluid (LF)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Conventional acidic lactate-buffered fluid (CF)
Number of subjects: 91
Study: 16925289

Group type: EXPERIMENTAL
Intervention: Totally robotic laparoscopic Roux-en-Y gastric bypass (TRRYGB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 50
Study: 12538422

Group type: EXPERIMENTAL
Intervention: Enoxaparin (1 mg/kg subcutaneously twice daily)
Number of subjects: 746

Group type: COMPARATOR
Intervention: Unfractionated heparin (70-U/kg bolus; 15 U x kg(‐1) x h(‐1) infusion for 48 hours)
Number of subjects: 746
Study: 10492111

Group type: EXPERIMENTAL
Intervention: HPV 16 and 18 testing in conjunction with repeat cytology
Number of subjects: 304

Group type: COMPARATOR
Intervention: Repeat cytology alone
Number of subjects: 304
Study: 8559201

Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg) as a four-hour intravenous infusion given every four weeks for nine cycles
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg)
Number of subjects: 392
Study: 1873266

Group type: EXPERIMENTAL
Intervention: BSS Plus
Number of subjects: 2

Group type: COMPARATOR
Intervention: S‐MA2
Number of subjects: 2
Study: 6194568

Group type: EXPERIMENTAL
Intervention: Nasogastric suction and intravenously administered fluids (SD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral intake of clear fluids (FF)
Number of subjects: 50
Study: 31070545

Group type: EXPERIMENTAL
Intervention: pegylated interferon (PEG‐IFN) alfa‐2a and ribavirin
Number of subjects: 715
Study: 27520087

Group type: EXPERIMENTAL
Intervention: Topical dexamethasone and hydroxypropyl methylcellulose (treatment group)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Topical dexamethasone (control group)
Number of subjects: 128
Study: 25495859

Group type: EXPERIMENTAL
Intervention: Siphon water filter with educational messages
Number of subjects: 191
Study: 23300977

Group type: EXPERIMENTAL
Intervention: Cannabis smoking (low Δ(9)‐Tetrahydrocannabinol blood concentrations)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cannabis smoking
Number of subjects: 31
Study: 20736891

Group type: EXPERIMENTAL
Intervention: Minimally invasive lumbar microdiscectomy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Open lumbar microdiscectomy
Number of subjects: 20
Study: 19245362

Group type: EXPERIMENTAL
Intervention: Enteral iron supplementation (ferrous sulfate 325 mg three times daily)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 17135335

Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03%
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: latanoprost 0.005%
Number of subjects: 48

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study: 15133003

Group type: EXPERIMENTAL
Intervention: Insulin-resistant group (IR)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Insulin-sensitive group (IS)
Number of subjects: 12
Study: 12100461

Group type: EXPERIMENTAL
Intervention: Various study designs (case-control, cohort, randomized trials)
Number of subjects: 0
Study: 9821410

Group type: EXPERIMENTAL
Intervention: Itraconazole (ITZ) without famotidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Itraconazole (ITZ) with famotidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of ITZ with and without famotidine
Number of subjects: 0
Study: 7655447

Group type: EXPERIMENTAL
Intervention: Dynamic exercise in patients with essential hypertension (ESH)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Dynamic exercise in healthy controls (C)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Dynamic exercise in ESH with left ventricular hypertrophy (LVH+)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Dynamic exercise in ESH without left ventricular hypertrophy (LVH‐)
Number of subjects: 37
Study: 2576360

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 10 mg picumast dihydrochloride
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral administration of 10 mg picumast dihydrochloride
Number of subjects: 16

Group type: COMPARATOR
Intervention: Comparison to healthy subjects
Number of subjects: 16
Study: 796401

Group type: EXPERIMENTAL
Intervention: 40 gms. galactose
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 50 gms. arabinogalactan and 0.11 gm. sodium saccharin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2 gm. methyl cellulose and 0.083 gm. sodium saccharin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 4 gm. galactose
Number of subjects: 18
Study: 7011356

Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate 0.05% (Eumovate)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Hydrocortisone butyrate 0.1% (Locoid)
Number of subjects: 2
Study: 31597151

Group type: EXPERIMENTAL
Intervention: Aerobic exercise during hemodialysis 3 times a week for 4 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 30
Study: 29672965

Group type: EXPERIMENTAL
Intervention: 103-mg p-synephrine (S)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Caffeine + 104-mg p-synephrine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 240-mg caffeine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 337-mg caffeine + 46-mg p-synephrine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 325-mg caffeine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 16
Study: 27012397

Group type: EXPERIMENTAL
Intervention: TAVR in patients aged ≥90 years
Number of subjects: 3773

Group type: COMPARATOR
Intervention: TAVR in patients aged <90 years
Number of subjects: 3773
Study: 24461464

Group type: EXPERIMENTAL
Intervention: Continuous wound infiltration of local ropivacaine (CWI group, n=29)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous fentanyl and ketorolac infusion on demand by patient‐controlled analgesia (IV PCA group, n=31)
Number of subjects: 60
Study: 21883496

Group type: EXPERIMENTAL
Intervention: Zearalenone (ZEA) at 2 mg/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Isoflavone (ISO) at 600 mg/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Simultaneous addition of ZEA and ISO
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Zearalenone (ZEA)
Number of subjects: 90
Study: 19488681

Group type: EXPERIMENTAL
Intervention: Magnesium citrate (1,830 mg/day) for 30 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 20
Study: 17335689

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (growth factors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Growth factors as chemotherapy-sensitizing agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Growth factor monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Growth factors administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Growth factors in younger patients with acute myeloid leukemia with normal karyotype
Number of subjects: 0
Study: 12781094

Group type: EXPERIMENTAL
Intervention: AAS (100 mg/day) on awakening
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: AAS (100 mg/day) before bedtime
Number of subjects: 64

Group type: COMPARATOR
Intervention: Non-pharmacological hygienic-dietetic recommendations
Number of subjects: 64
Study: 10682031

Group type: EXPERIMENTAL
Intervention: Aerosolized tobramycin (6 mg/kg/day, n = 21)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (n = 17)
Number of subjects: 38
Study: 9100167

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.15 mg/kg, intravenously, once on admission), colchicine (0.5 mg, orally, daily, for 3 days), pentoxifylline (400 mg, orally, daily, for 3 days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (not given DCP)
Number of subjects: 26
Study: 8402761

Group type: EXPERIMENTAL
Intervention: Triflusal (300 mg t.i.d.; n = 143)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo (n = 138)
Number of subjects: 281